S21 Stock Overview
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
S2Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0071 |
| 52 Week High | kr0.11 |
| 52 Week Low | kr0.0002 |
| Beta | 0.94 |
| 1 Month Change | 4.41% |
| 3 Month Change | -22.83% |
| 1 Year Change | -80.49% |
| 3 Year Change | -98.87% |
| 5 Year Change | -99.63% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| S21 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -17.4% | -1.2% | -1.2% |
| 1Y | -80.5% | -10.6% | 1.8% |
Return vs Industry: S21 underperformed the German Medical Equipment industry which returned -9.6% over the past year.
Return vs Market: S21 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| S21 volatility | |
|---|---|
| S21 Average Weekly Movement | 20.1% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S21's share price has been volatile over the past 3 months.
Volatility Over Time: S21's weekly volatility has decreased from 174% to 20% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 20 | Petter Sivlér | www.s2m.se |
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover.
S2Medical AB (publ) Fundamentals Summary
| S21 fundamental statistics | |
|---|---|
| Market cap | €1.96m |
| Earnings (TTM) | -€1.94m |
| Revenue (TTM) | €769.02k |
2.6x
P/S Ratio-1.0x
P/E RatioIs S21 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S21 income statement (TTM) | |
|---|---|
| Revenue | kr9.02m |
| Cost of Revenue | kr2.69m |
| Gross Profit | kr6.34m |
| Other Expenses | kr29.05m |
| Earnings | -kr22.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.082 |
| Gross Margin | 70.23% |
| Net Profit Margin | -251.63% |
| Debt/Equity Ratio | 0% |
How did S21 perform over the long term?
See historical performance and comparison